- In October 2024, Dr. Reddy's Laboratories announced its collaboration with Gilead Sciences for the manufacturing and commercialization of the HIV drug Lenacapavir in India and 120 other countries. The company has secured a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, marking a significant step in expanding access to HIV treatment in these regions
- In December 2023, Zydus Lifesciences received approval from the U.S. Food and Drug Administration (USFDA) to market a generic antiviral medication, Darunavir Tablets, for the treatment of HIV-1 infections. This approval opens new access to affordable HIV treatments in the U.S. market
- In August 2023, Aurobindo Pharma Ltd. launched its HIV triple combination product specifically designed for children living with HIV in low- and middle-income countries. With a voluntary pediatric dolutegravir license from ViiV Healthcare, Aurobindo can supply the product across 123 LMICs, including India
- In February 2023, Mylab Discovery Solutions, based in Pune, introduced three rapid kits for the early detection of sexually transmitted infections (STIs), including HIV, Hepatitis C, and Syphilis. These innovations aim to address the growing global burden of STIs, with the World Health Organization (WHO) projecting a daily caseload of one million STIs worldwide
- In August 2022, Gilead Sciences achieved a major milestone with the European Commission’s approval of Sunlenca (Lenacapavir), the first global regulatory approval for this novel treatment. Available in both injection and tablet forms, Sunlenca targets multi-drug-resistant HIV infections and is to be used alongside other antiretroviral therapies, offering new hope to patients facing limited treatment options
